A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and G (Q57903847)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and G	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

endometrial carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Massimo Di Maio

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Maria Gabriella Ferrandina

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Domenica Lorusso

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Vittorina Zagonel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

S Pignata

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

G Scambia

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

C Pisano

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

E Breda

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

S Greggi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

A Febbraro

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

N Riva

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

V De Rosa

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

C Gallo

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

F Perrone

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

0 references

publication date

8 May 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

British Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

96

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1639-1643

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603787

0 references

Systematic review of systemic therapy for advanced or recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Current treatment options for endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603787

21 January 2018

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359926

30 November 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359926

30 November 2018

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17486128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17486128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17486128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17486128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/17486128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603787

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17486128%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57903847&oldid=1774232835"